Brief: Dyadic Announces Top-Line Results From Its Successful Phase 1 Clinical Trial For A First-In-Human Filamentous Fungal-Based Vaccine Candidate

Dyadic International

29/11/2023 15:59

Dyadic International Inc  DYAI.O :
    * DYADIC ANNOUNCES TOP-LINE RESULTS FROM ITS SUCCESSFUL
PHASE 1
CLINICAL TRIAL FOR A FIRST-IN-HUMAN FILAMENTOUS FUNGAL-BASED
VACCINE CANDIDATE
    * DYADIC INTERNATIONAL INC: NO SERIOUS ADVERSE EVENTS
REPORTED
    * DYADIC INTERNATIONAL INC: C1-CELL PRODUCED ANTIGEN WAS
BOTH SAFE
AND WELL-TOLERATED
    * DYADIC INTERNATIONAL INC: DEMONSTRATED SAFETY AND
REACTOGENICITY
OF DYAI-100 RECOMBINANT PROTEIN
    * DYADIC INTERNATIONAL INC - PRIMARY ENDPOINT MET
    * DYADIC INTERNATIONAL INC: PRIMARY ENDPOINT MET

Source text for Eikon:  ID:nGNX1HspzG 
Further company coverage:  DYAI.O